COOCooper Companies (The)

$72.67

Is the price fair?

What COO's price assumes

Cooper Companies (The) trades at 62.1× earnings against 42.5× for the median Medical Instruments & Supplies name, more expensive than its own group.

62.1

Trailing P/E · Medical Instruments & Supplies median 42.5 · 1.46× the median: the market pays up for this one

Price / sales
2.90

Price / sales · as of 2026-Q2

Free cash flow yield
4.4%

Free cash flow yield · Medical Instruments & Supplies median 3.7%

Growth the price implies
+7.2%

Growth the price implies · The price pays for +7.2% free cash flow growth a year for a decade; the business has delivered +14% a year over the last three.

Details
Price / book2026-Q2
1.49
EV / EBIT2026-Q2
28.1
EV / sales2026-Q2
3.31
Healthcare median P/E362 names
31.5
Medical Instruments & Supplies median P/E29 names
42.5
Free cash flow, trailing twelve months
$570M
Market capitalisation
$12.9B
3-year revenue growth
+7.3%
3-year free cash flow growth
+14%
COO has re-rated away from its own history, so multiplying the old multiple by today's earnings prices a full reversal, not the business
MethodPer share
What its own history would implynot meaningful, 41.6× today against a 16.7× median
52-week range$58.98 – $84.32
Today$72.67

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.